Risk Management and Application of Artificial Intelligence in Elderly Patients with Chronic Diseases and Sarcopenia

Qinqin Chen[1,#], Yinhang Wu[2,#], Chenyu Li[3,#], Xuecan Yang[4], Laurent Peyrodie[5], Jean-Marie Nianga[6], Zefeng Wang[1,3,4,5,6,*]

[1]ASIR, Institute - Association of Intelligent Systems and Robotics, Paris, France
[2]Huzhou Central Hospital, Affiliated Central Hospital Huzhou University, Huzhou, Zhejiang, China
[3]Huzhou University, Huzhou, Zhejiang, China
[4]IEIP, Institute of Education and Innovation in Paris, Paris, France
[5]ICL, Junia, Université Catholique de Lille, LITL, F-59000 Lille, France
[6]Sino-Congolese Foundation for Development, Brazzaville, Republic of the Congo
[#]These Authors Contributed Equally to This Work.
**Corresponding Author.*

Abstract: This study investigates AI's incorporation in healthcare, focusing on chronic diseases and sarcopenia in the elderly. It explores AI's potential to enhance risk management and patient outcomes, especially for cardiovascular disease, diabetes, and COPD. The research highlights AI-driven tools' efficacy in early diagnosis, personalized treatment, and continuous health monitoring, improving elderly patients' quality of life. Legal and ethical issues are covered, including bias in AI models, patient data privacy, and regulatory compliance. The study emphasizes the need for interdisciplinary collaboration and empirical validation. The future of artificial intelligence in the healthcare field, with wearable technology and personalized treatment plans, is expected to bring revolutionary patient care. The paper also considers economic implications, advocating for regulatory frameworks and equitable access. AI can transform chronic disease and sarcopenia management through better diagnostics and proactive health management, but ongoing research and collaboration are essential to tackle ethical, legal, and practical challenges, aiming for an efficient, effective, and equitable healthcare system.

Keywords: Artificial Intelligence; Chronic Diseases; Sarcopenia; Healthcare Risk Management; Personalized Medicine

1. Introduction

1.1 Background

An important development in healthcare is the use of artificial intelligence (AI), especially for seniors with sarcopenia and chronic illnesses. The incidence of chronic illnesses and sarcopenia rises with the aging of the world population—the UN predicts that by 2050, one in six individuals will be 65 or older. Elderly populations commonly suffer from cardiovascular disease, diabetes, and COPD, which reduce quality of life and raise healthcare costs, with 95% of older adults having at least one chronic condition. Sarcopenia exacerbates these issues, increasing the risks of falls, fractures, and disabilities. Traditional risk management strategies are inadequate for these complex needs. AI offers innovative solutions through advanced data analysis, predictive modeling, and personalized interventions, utilizing computer vision, natural language processing, and machine learning to improve patient care, predict disease progression, and optimize treatment plans [1-3].

1.2 Purpose of the Study

The purpose of this study is to elucidate how artificial intelligence might enhance risk management for senior citizens suffering from sarcopenia and chronic illnesses. AI integration in healthcare offers a promising solution to these complex challenges by enhancing the identification, assessment, and management of associated risks. The study explores AI's potential in early diagnosis, personalized treatment planning, continuous health monitoring, and predictive analytics, ultimately improving patient outcomes and reducing healthcare system burdens. The objective is to comprehensively understand how AI can transform risk management practices, focusing on elderly populations.

1.3 Research Objectives

In order to achieve the objective of this study, the following research objectives have been identified:

- **Point out the difficulties in** caring for older patients who have sarcopenia and chronic illnesses, emphasizing the shortcomings of the methods used in risk management today.
- **Investigate AI tools and techniques** that can enhance risk management for elderly patients. This includes exploring the use of AI in predictive analytics, personalized treatment, and continuous monitoring.
- **Propose AI-driven strategies** for improving patient outcomes. These strategies will focus on integrating AI into clinical workflows to optimize risk management practices and provide personalized care.

The potential of artificial intelligence (AI) to analyze large volumes of data properly and efficiently could revolutionize the treatment of chronic illnesses and age-related muscle degradation, ultimately leading to an improvement in the quality of life for senior citizens. This study intends to add to the expanding corpus of knowledge on artificial intelligence in healthcare and offer useful insights for healthcare practitioners by tackling the specified research objectives.

1.4 The Article's Structure

This paper begins with a review of demographic changes and the burden of chronic diseases and sarcopenia in older patients. It then systematically investigates AI's role in improving risk management for these patients, as seen in Figure1. It then analyzes current risk management practices and challenges. The integration of AI in healthcare, focusing on chronic disease and sarcopenia management, is examined, including technologies, data processing techniques, and implementation. AI-driven risk management strategies and real-world applications are presented, highlighting tangible benefits. In addition, the paper discusses future paths for AI research, patient privacy, data security, fairness, ethical and legal issues, and legislative suggestions to assist AI integration in healthcare.



Figure 1. Structure of This Article

2. Overview of Risk Management in Healthcare

2.1 Definition and Principles

The objective of risk management in healthcare is to identify, assess, and mitigate risks to improve patient safety and care quality. This involves preventing errors, enhancing patient safety, and creating policies to manage risks. Due to human error, technological failures, and procedural inefficiencies, risk management is complex. Principles include comprehensive risk assessment, proactive risk identification, implementing risk control measures, and continuous monitoring and evaluation. Effective risk management requires a deep understanding of the healthcare environment, specific risks, and their impact on patient outcomes, aiming to reduce adverse events and enhance overall safety[4].

2.2 Importance in Elderly Care

Risk management in elderly patients is challenging due to their susceptibility to health conditions and complications. Aging leads to a decline in physiological functions, making the elderly more prone to chronic diseases like cardiovascular disease, diabetes, and COPD, which increase hospitalization rates and healthcare needs. Effective risk management is crucial for enhancing patient safety, improving health outcomes, and reducing healthcare costs. For instance, enhanced primary healthcare for high-risk elderly patients reduces hospitalizations, and integrating pharmacists in emergency care lowers unplanned readmissions by addressing medication issues. Managing conditions like NSTEMI requires tailored risk management due to age-related factors. Holistic nursing models improve elderly patients' mental state and satisfaction, highlighting the benefits of comprehensive, patient-centered risk management strategies[5].

2.3 Current Risk Management Practices

Identifying, evaluating, and reducing risks through incident reporting, root cause analysis, and protocol development are the traditional methods of risk management in the healthcare industry. However, these methods are often reactive, addressing risks only after they occur, leading to delayed interventions and suboptimal patient outcomes, especially in elderly care. Elderly patients face complex risks due to multiple chronic conditions and polypharmacy. Advanced technologies like AI and IoT can overcome these limitations by enabling predictive analytics, early warning systems, and personalized risk assessments. AI-driven remote monitoring systems continuously track physiological data using Internet of Things (IoT) devices and sensors. This enables early diagnosis of health problems and prompt interventions. For instance, platforms like CARDIOCARE use AI to categorize elderly patients with chronic illnesses by their risk of cardiotoxicity, facilitating precise interventions. These technologies enhance risk management practices and deliver more personalized and effective healthcare for elderly patients[6,7].

3. Chronic Diseases in Elderly Patients

3.1 Epidemiology

The rising prevalence of chronic diseases among elderly populations represents a significant global public health concern. The number of senior people with chronic illnesses is rising along with the world population's ageing. Notably, this population is particularly prone to chronic conditions like diabetes, chronic obstructive lung disease (COPD), and cardiovascular disease. For example, cardiovascular diseases are the primary cause of mortality among elderly patients, markedly influencing their quality of life and healthcare expenditure[8]. Furthermore, diabetes represents a significant health concern, with a high prevalence among the elderly, leading to severe complications such as neuropathy, retinopathy, and cardiovascular issues[9]. Moreover, COPD contributes to the burden of chronic illnesses overall by impairing respiratory function and raising the risk of hospitalization and death in older individuals[10].

A study conducted in China revealed that elderly patients with chronic diseases encounter distinctive challenges due to the convergence of multiple chronic conditions, polypharmacy, and the declining efficacy of bodily functions. The study demonstrated the complicated interaction between chronic diseases and physical health outcomes by highlighting the considerable correlation between the number of chronic diseases and health-related behaviors as well as the incidence of falls among the elderly. Furthermore, the high prevalence of chronic diseases among elderly patients requires a comprehensive approach to healthcare that addresses the multifaceted nature of these conditions.

3.2 Effects on Well-Being and Life Quality

Elderly people' physical and mental health are significantly impacted by the incidence of chronic diseases. The continuous management of chronic conditions has the potential to result in psychological distress, reduced mobility, and a diminished quality of life. For instance, because of the complex interactions between various diseases, drugs, and deteriorating physiological processes, older individuals with chronic heart failure face significant challenges in controlling their condition. This complexity frequently results in a greater burden of self-management and an elevated risk of adverse health outcomes[11]. In addition, there are substantial financial costs associated with managing chronic illnesses, which put a strain on both individuals and healthcare systems. The financial burden of chronic disease is compounded by the costs of medication, frequent hospital visits and long-term care. It is therefore essential to explore efficient management strategies to alleviate these pressures.

The health results of senior individuals with chronic conditions are also significantly impacted by the social determinants of health, which include access to healthcare, socioeconomic status, and level of education. According to a Chinese study, elderly patients who had more drug regimens, higher pharmaceutical prices, and poorer educational attainment also had to deal with the larger burden of polypharmacy, which was mostly caused by concerns about costs and a lack of control over prescription regimens[12]. This underscores the need for focused initiatives that tackle the financial barriers to efficient chronic illness care and improve the general standard of living for senior citizens.

3.3 Risk Factors and Determinants

The development and progression of chronic diseases in elderly patients are influenced by a combination of genetic, environmental, and lifestyle factors. Genetic predispositions can serve to increase the likelihood of developing conditions such as diabetes and cardiovascular diseases. Environmental factors, including exposure to pollutants and poor living conditions, serve to further exacerbate the risk of chronic disease. In addition, a number of lifestyle factors, such as smoking, bad eating habits, and physical inactivity, are important in the development and course of chronic illnesses. It is imperative to acknowledge the significant role that multimorbidities play in complicating management efforts[13]. The presence of multiple chronic conditions in elderly patients presents a significant challenge in the prioritisation of treatments and the management of interactions between different medications.

In addition to the previously indicated elements, social support and mental health are crucial for the management of chronic illnesses. It has been demonstrated that elderly patients with robust social support networks and elevated levels of psychological capital are more likely to demonstrate superior self-management capabilities and favourable health outcomes. Conversely, social isolation and a lack of community support have been linked to an increased prevalence of depressive symptoms and poorer health outcomes. According to a study, social capital elements like a feeling of support from friends and family and a sense of community play a big role in the mental health of older people with chronic illnesses. This suggests that interventions targeting these social determinants could improve their overall health and well-being[14].

3.4 Management Strategies

The effective management of chronic diseases in elderly patients necessitates a multifaceted approach that integrates best practices, patient-provider relationships, and adherence to treatment plans. One promising strategy is the implementation of continuous nursing interventions in conjunction with comfort nursing, operating under a medical-nursing combination mode. This approach has been demonstrated to markedly enhance self-care capabilities and patient satisfaction among elderly patients with chronic illnesses. By delivering constant assistance and specialized care, healthcare professionals may aid patients in managing their ailments more successfully and enhance their quality of life.

Pharmacist-led pharmaceutical therapy management is another successful approach to treating chronic illnesses in senior citizens. According to a study, this strategy significantly improved health outcomes and reduced medication-related problems in elderly, ambulatory patients with chronic illnesses. In order to optimise the overall management of chronic diseases, pharmacists play a crucial role in teaching patients about their drugs, ensuring adherence to treatment plans, and recognizing potential drug interactions.

The treatment of chronic diseases in older individuals may be significantly improved by the incorporation of cutting-edge technology like artificial intelligence and network analytics. For example, the utilisation of AI to predict the duration of hospitalisation at the point of admission has demonstrated potential for optimising patient care and resource allocation[15]. Healthcare professionals may create more effective and individualized treatment plans by utilizing artificial intelligence and machine learning algorithms, which eventually leads to better patient results.

4. Sarcopenia in Elderly Patients

4.1 Definition and Diagnosis

Muscle mass, strength, and function are all reduced in sarcopenia, a gradual and widespread skeletal muscle condition. It is often identified in older individuals and linked to poor health outcomes, such as increased mortality, low quality of life, and physical disability. reduced muscle mass, reduced muscle strength, and poor physical performance are among the diagnostic criteria set by the European Working Group on Sarcopenia in Older People (EWGSOP) [16]. A variety of instruments and methods are used to evaluate sarcopenia, such as grip strength tests to measure muscle strength, gait speed assessments to evaluate physical performance, and imaging techniques like dual-energy X-ray absorptiometry (DEXA) and bioelectrical impedance analysis (BIA) to measure muscle mass.

Recent research has concentrated on the development of alternative diagnostic criteria that can be applied to specific patient populations. One potential diagnostic criterion for sarcopenia in older people with type 2 diabetes mellitus (T2DM) is the alternative skeletal muscle index (a-SMI). This index considers a number of factors, including gender, obesity status, vitamin D levels and hypertension history. It has been shown to have a high level of agreement with the 2019 criteria set out by the Asian Working Group for Sarcopenia (AWGS)[17]. Such advancements in diagnostic methods are critical to the early identification and prompt treatment of sarcopenia.

4.2 Prevalence and Risk Factors

The frequency of sarcopenia varies significantly based on the population being studied and the diagnostic standards used. The prevalence is noticeably high in older people with chronic diseases such diabetes, hypertension, and chronic renal disease. Sarcopenia, for instance, is significantly correlated with several risk variables, such as age, male sex, body mass index (BMI), glycated hemoglobin (HbA1c) levels, diabetic nephropathy, and decreased serum albumin levels, according to a study of elderly people with type 2 diabetes mellitus (T2DM)[18].

Sarcopenia can be caused by a number of risk factors, such as chronic inflammation, malnourishment, physical inactivity, and the presence of comorbidities. Given that consistent exercise is necessary to maintain muscle mass and strength, physical inactivity plays a major role. It has been shown that malnutrition, in particular a lack of protein, aggravates muscle wasting and reduces muscle function. Furthermore, chronic inflammation, which is often associated with the ageing process and chronic diseases, also plays a significant role in the pathogenesis of sarcopenia[19].

When it comes to managing sarcopenia, nutritional aspects are crucial. Frequent consumption of green and yellow vegetables was positively correlated with the absence of sarcopenia in an elderly patient population with chronic renal disease receiving conservative treatment, according to a cross-sectional study. This demonstrates how important eating habits are to managing and preventing sarcopenia.

4.3 Consequences

Elderly patients' independence and health are significantly impacted by sarcopenia. It significantly affects mobility, which raises the risk of falls and fractures and makes it harder to carry out everyday tasks. Sarcopenia-related loss of muscle mass and strength can set off a vicious cycle of deteriorating physical abilities and impairment. An elevated sarcopenia index (SI) was found to be adversely correlated with the incidence of stroke in a cohort study of older adults with hypertension, suggesting that muscle health is protective against serious cardiovascular events.

Furthermore, sarcopenia has been demonstrated to impact surgical outcomes in elderly patients. For instance, in older patients undergoing surgery for oral squamous cell carcinoma, a low skeletal muscle index (SMI) has been linked to longer hospital stays, a higher incidence of severe postoperative complications, and a higher overall complication index[20]. This emphasizes how improving surgical outcomes requires preoperative sarcopenia care and assessment.

The therapy of sarcopenia is further complicated by its interactions with other chronic conditions. Sarcopenia is commonly connected with other diseases like malnutrition and cachexia in older adults with type 2 diabetes. This necessitates the implementation of comprehensive treatment strategies that address all of these factors simultaneously[21]. The coexistence of sarcopenia and atrial fibrillation has been linked to an elevated risk of heart failure, underscoring the augmented vulnerability of patients with multiple comorbidities[22].

4.4 Screening and Intervention

Sarcopenia must be identified early and regularly screened for in order for treatment to be effective. For first evaluation, screening instruments like the SARC-F questionnaire are frequently used. It evaluates strength, help in walking, getting out of a chair, ascending stairs, and falls. Additional assessment is carried out by means of imaging methods and physical performance assessments. The timely execution of intervention is crucial in preventing the advancement of sarcopenia, and it is made possible by early identification.

The goal of treating sarcopenic older individuals is to increase muscle mass and function by a combination of pharmaceutical, dietary, and exercise therapies. The most efficacious physical activities for enhancing muscle strength and function are resistance training and aerobic exercise. Nutritional interventions are designed to increase protein intake and ensure adequate micronutrient consumption. Branching-chain amino acid (BCAA) therapy has shown promise in the management and avoidance of sarcopenia. However, the effectiveness of this strategy depends on the person in question's total protein intake.

New treatment modalities are being researched in addition to diet and exercise. For instance, it has been shown that senior sarcopenic patients who practice Tai Chi, a mind-body exercise, experience improved neuromuscular reflexes and postural control. Twelve weeks of Tai Chi dramatically improved balance and decreased the likelihood of falls in this cohort, according to a randomised controlled research.

It is imperative that comprehensive treatment strategies combining physical, nutritional and pharmacological interventions be employed in order to effectively manage sarcopenia. The implementation of bespoke strategies that are tailored to the specific requirements and circumstances of elderly patients has the potential to markedly enhance their quality of life whilst simultaneously reducing the likelihood of adverse health outcomes.

5. Role of Artificial Intelligence in Healthcare

5.1 AI in Managing Chronic Diseases

The management of chronic diseases has undergone a significant change with the introduction of artificial intelligence (AI), with applications in diagnosis, treatment planning, and monitoring being key components of this change. Artificial intelligence technologies employ machine learning algorithms, data analytics, and predictive modelling to facilitate enhanced clinical decision-making, thereby enabling more precise and efficient interventions.

One particularly noteworthy application of AI is in the diagnosis of chronic diseases through the utilisation of medical imaging datasets. Numerous imaging modalities, such as CT, MRI, mammography, and ultrasound, are used to diagnose a wide range of illnesses, such as Alzheimer's disease, diabetes, cancer, heart disease, and chronic obstructive pulmonary disease (COPD). Artificial intelligence systems are capable of analysing these images with high accuracy, frequently exceeding the capabilities of traditional diagnostic methods in terms of speed and precision[23]. For instance, AI algorithms are capable of detecting the initial indications of diabetic retinopathy from retinal images, thereby facilitating prompt interventions that can avert vision impairment in diabetic patients.

Artificial intelligence has shown significant promise in the field of treatment planning, particularly in the area of individualized care for patients with chronic illnesses. AI is able to offer treatment programs that are individualized and maximize results by analyzing patient data, including genetic information, medical history, and lifestyle factors. The efficacy of machine learning algorithms, like the k-nearest neighbours (KNN) algorithm, in categorising patients according to their risk profiles was illustrated in a study on coronary heart disease (CHD). This may help with the creation of individualized treatment plans for CHD patients[24]. Predictive analytics powered by artificial intelligence can also be used to identify people who are at a high risk of developing an illness, allowing for early detection and proactive treatment.

Another area in which AI demonstrates particular efficacy is that of monitoring chronic diseases. The continuous monitoring of physiological parameters, such as heart rate, blood glucose levels and respiratory function, using AI-powered wearable devices and remote patient monitoring systems enables the real-time tracking of these variables. Such systems provide alerts for abnormal readings, thus enabling healthcare providers to intervene promptly and adjust treatment plans as required. For example, the utilisation of AI in the management of COPD has been demonstrated to enhance patient outcomes by expediting the identification of exacerbations and optimising treatment regimens[25].

Another example of AI's usefulness in the treatment of chronic illnesses is its combination with wearable technologies and blockchain. This combination offers smart recommendations for illness management based on real-time physiological data, while also improving the security and transparency of healthcare data. In the realm of smart healthcare, the combination of wearable technology, blockchain technology, and artificial intelligence (AI) offers fresh options for the management of chronic diseases[26].

5.2 AI in Managing Sarcopenia

Sarcopenia, which is characterized by a decrease in muscle mass, strength, and function, poses a serious problem for older people. Artificial intelligence (AI) is becoming more and more popular in the detection and treatment of sarcopenia, opening up new possibilities for bettering patient care. The current generation of AI technologies is capable of analysing a diverse array of data, including imaging, physical performance tests and clinical records, in order to identify the early indications of sarcopenia and to monitor its progression.

The utilisation of machine learning and deep learning algorithms in the diagnostic domain of artificial intelligence (AI) holds promise for improving the precision of sarcopenia evaluations. By using imaging techniques like dual-energy X-ray absorptiometry (DEXA) and bioelectrical impedance analysis (BIA), these instruments can analyze muscle mass and function. The automation of image processing by AI minimizes the possibility of human error and gives more consistent and accurate outcomes[27].

Using wearable sensors and motion capture devices, artificial intelligence (AI) can be utilized in the management of sarcopenia to evaluate gait patterns and balance, thereby predicting the risk of falls and fractures. Such predictions allow healthcare providers to implement targeted interventions, such as strength training and balance exercises, in order to mitigate the risk of falls and improve overall mobility[28]. Furthermore, AI has the capacity to customise exercise and dietary plans according to patient profiles, guaranteeing that interventions are suited to the unique requirements and circumstances of every patient.

Further developments in AI for sarcopenia management will likely involve the creation of more sophisticated algorithms capable of integrating diverse data sources, including genetic information, environmental factors, and lifestyle habits. These developments will facilitate a more comprehensive understanding of sarcopenia and its underlying causes, thereby enabling the formulation of more effective prevention and treatment strategies[29].

5.3 Data Processing and Feature Extraction

The quality and quantity of data that is accessible for analysis determines how effective AI will be in the healthcare industry. Crucial phases in the creation of reliable AI models are data processing and feature extraction. Methods for gathering and analysing relevant health data include the use of wearable technology, mobile health apps, and electronic health records (EHRs).

Electronic health records (EHRs) constitute a rich source of both structured and unstructured data, which can be employed in the training of AI models. Artificial intelligence (AI) can recognize patterns and connections that human clinicians might not be able to easily notice by extracting relevant information from imaging reports, laboratory results, and clinical notes. Natural language processing (NLP) techniques are especially beneficial for the extraction of meaningful information from unstructured text within electronic health records (EHRs), thus facilitating more comprehensive data analysis[30].

Heart rate, activity level, and sleep patterns are just a few of the physiological indicators for which wearable technology and mobile health apps produce constant data streams. Machine learning algorithms can process the data in real time, allowing for the detection of anomalies and the prediction of health events. To illustrate, AI-powered blood pressure monitoring systems are capable of analysing trends and providing personalised treatment recommendations based on individual patient data. Such systems facilitate enhanced communication between patients and healthcare providers, thereby improving chronic disease management and patient outcomes.

Another essential component of AI in healthcare is the extraction of characteristics from medical pictures. Convolutional neural networks (CNNs), one of the more sophisticated imaging approaches, can automatically recognize pertinent features from computed tomography (CT), magnetic resonance imaging (MRI), and X-ray pictures. The automated feature extraction process facilitates the acceleration of the diagnostic process and enhances accuracy, particularly in complex cases such as sarcopenia, where the consideration of multiple factors is essential[31].

5.4 Diagnostic Imaging and AI Integration

The incorporation of AI into diagnostic imaging technologies has led to a significant enhancement in the precision and expediency of medical diagnoses. Clinical decision-making can be supported by artificial intelligence algorithms that improve image quality, identify anomalies, and measure the severity of diseases.

Artificial intelligence-enhanced imaging techniques can be used to quantify muscle mass and quality correctly in the context of sarcopenia. These measurements are of great importance for the diagnosis of sarcopenia and the assessment of its severity. The integration of AI with imaging modalities such as MRI and DEXA enables clinicians to obtain comprehensive assessments of muscle composition and function, thereby facilitating the early detection and intervention of sarcopenia.

AI is also essential for the detection and evaluation of other disorders that are commonly linked to sarcopenia, such as osteoporosis and frailty. For instance, AI algorithms can analyse bone density scans to identify the early indications of osteoporosis, thereby enabling prompt intervention to prevent fractures and enhance bone health. The integration of AI with diagnostic imaging techniques offers a comprehensive approach to the management of conditions affecting elderly patients[32].

The future of AI in diagnostic imaging will be characterised by the development of more advanced algorithms capable of integrating multimodal data, such as combining imaging data with genetic and clinical information. This all-encompassing strategy will enable more accurate and customized diagnoses, improving patient outcomes and reducing the strain on healthcare systems[33].

6. AI-Driven Risk Management Strategies

6.1 Enhancing Clinical Risk Management

Clinical risk management has undergone a radical transformation with the introduction of artificial intelligence (AI), which provides sophisticated instruments for risk assessment and reduction. Artificial intelligence (AI) technologies analyze vast volumes of healthcare data, detect potential dangers, and recommend preventative steps by using machine learning algorithms, predictive analytics, and natural language processing (NLP). By taking a proactive stance, healthcare providers can foresee and promptly address risks, averting unfavorable outcomes.

Artificial intelligence (AI) offers several benefits in risk management, chief among them the ability to analyze complex datasets and identify patterns that human analysts might find difficult to identify. To illustrate, AI-driven models are capable of predicting patient outcomes through the analysis of historical data, clinical notes, and imaging studies. This capacity is especially beneficial in the context of chronic disease management, where the early identification of risk factors can markedly enhance patient outcomes. Artificial intelligence (AI) tools, including Random Forest and Support Vector Machines, have been effectively employed to augment the precision of coronary heart disease risk prediction, underscoring factors such as age, cholesterol levels, and smoking behaviour[34]. It has been shown that using AI-driven risk assessment tools in healthcare contexts improves patient safety and the standard of treatment given. AI algorithms, for instance, have been used to predict the likelihood of readmissions from hospitals, allowing medical professionals to carry out focused interventions that lower readmission rates. These prediction models identify patients who are likely to need further monitoring and follow-up care by analyzing patient data from electronic health records (EHRs)[35]. These models' long-term accuracy and applicability are guaranteed by AI's ability to learn new things on a regular basis and adjust to new information.

The incorporation of AI into clinical workflows has also been demonstrated to facilitate the optimal distribution of resources and enhance operational efficiency. By forecasting patient inflows and identifying periods of high demand, AI can assist healthcare administrators in making data-driven decisions about staffing, resource allocation, and scheduling. This optimisation has the effect of reducing the burden on healthcare facilities and ensuring the availability of resources at the times and in the locations where they are needed most [36].

6.2 Supporting Decision-making for Older Adults

Applications of artificial intelligence (AI) are crucial to the field of geriatric care because they help senior citizens make decisions more easily. This is achieved through the provision of personalised care plans and tools that assist healthcare professionals in making well-informed decisions. Through a thorough analysis of patient data, including genetic information, lifestyle characteristics, and clinical history, the use of AI in the field of personalized medicine enables the creation of customized treatment programs.

Artificial intelligence-driven decision support systems are capable of recommending personalised interventions through the analysis of a multitude of data sources. To give an example, the iHELP system combines AI with extensive medical information to enable person-centered early risk prediction and intervention strategies. The system allows healthcare providers to adapt interventions to the specific requirements of each patient, thereby enhancing the efficacy of care and reducing the likelihood of adverse events.

AI-driven technologies have the ability to offer real-time patient health insights in the context of managing chronic diseases in older persons, hence enabling a proactive approach to condition management. For example, artificial intelligence algorithms can be employed to analyse continuous glucose monitoring data in order to predict episodes of hyperglycaemia or hypoglycaemia in patients with diabetes. Such predictions permit the implementation of timely adjustments to medication and lifestyle interventions, thereby reducing the risk of complications and improving overall glycemic control[37].

Furthermore, AI-powered systems can facilitate the management of complex cases by offering decision support to healthcare professionals. To illustrate, AI algorithms can facilitate the administration of care to patients with multiple chronic conditions. This is achieved by identifying potential drug interactions and suggesting alternative treatments. This functionality is of particular value in the field of geriatrics, where the use of multiple medications and the presence of multiple comorbidities are prevalent[38].

6.3 Mobile Health Applications

The proliferation of mobile health (mHealth) applications has considerably extended the scope of AI-driven risk management strategies. With the use of AI-powered mobile apps, patients may take an active part in their own care and receive real-time insights into their health state through personalized feedback and continuous health monitoring.

Artificial intelligence-enabled mobile health apps may track a number of physiological metrics, such as blood pressure, heart rate, and degree of physical activity. Such applications employ machine learning algorithms to identify irregularities and offer tailored suggestions for lifestyle modifications or medical interventions. For example, AI-driven blood pressure monitoring applications can analyse trends in blood pressure readings and suggest adjustments to medication or lifestyle based on individual patient data.

Numerous case studies have illustrated how AI-driven mobile health applications can enhance patient outcomes. For instance, a text messaging-based intervention showed promise in lowering HbA1C levels and increasing the percentage of participants who achieved target glycemic control in patients with diabetes mellitus and coronary heart disease[39]. These instances highlight the potential of mobile health apps to support patient self-care and make managing chronic illnesses easier.

In addition to their utility in the context of individual patient care, AI-powered mHealth applications can also be employed in the monitoring of public health and the management of crises. During the course of the global pandemic caused by the novel coronavirus, artificial intelligence and big data analytics tools were employed to monitor disease trends, predict the occurrence of outbreaks and assist in the formulation of strategic plans for the management of crises. The aforementioned applications furnished invaluable insights that informed public health interventions and the distribution of resources[40].

6.4 Case Studies and Real-world Applications

The useful uses of AI in risk management demonstrate the technology's potential to revolutionize the healthcare industry. For example, AI technologies have been employed in the screening and management of bladder cancer, facilitating early detection and personalised treatment through predictive models and AI-driven technologies[41]. Due to their ability to enable timely and accurate therapies, these advancements have the potential to significantly improve patient outcomes.

The use of AI in the treatment of cardiovascular disorders is another important use. Risk prediction models have been developed using artificial intelligence (AI) in an effort to improve the accuracy of cardiovascular event forecasting and provide proactive management advice. These models employ machine learning techniques, including SVM, KNN, and Random Forest, to analyse clinical data and identify high-risk patients. The incorporation of AI into the domain of cardiovascular care has been demonstrated to improve patient outcomes by enabling the implementation of early intervention and the development of personalised treatment plans.

AI has also had a major impact on medical imaging, specifically in the area of coronary computed tomography angiography (CCTA) image analysis. The application of AI algorithms to the analysis of CCTA images enables the automation and refinement of this process, thus facilitating more accurate risk stratifications for the management of coronary artery disease. This capability enhances the accuracy of diagnosis and facilitates precise treatment planning[42].

Furthermore, AI-driven systems have been developed with the objective of managing asthma risks. This has involved enhancing logistic regression models and improving quantile regression models. These systems provide substantial enhancements in classification accuracy and low relative errors, thereby facilitating more precise risk assessment and intervention strategies for patients with asthma.

A number of benefits arise from applying AI to the field of healthcare risk management, such as improved patient outcomes, more efficient resource allocation, and improved clinical decision-making procedures. AI-driven risk management techniques can solve the complex difficulties of modern healthcare and enable the delivery of more individualized and effective care by utilizing advanced data analytics and machine learning algorithms.

7. Ethical and Legal Considerations

7.1 Privacy and Data Security

Ensuring the security and confidentiality of patient data is crucial in the healthcare industry when using artificial intelligence (AI) applications. The amount of sensitive health data being gathered, processed, and kept has increased along with the incorporation of AI technologies, raising serious concerns about patient confidentiality and data security. All AI-driven healthcare systems must comply with the strict criteria for data privacy and security set out by the Health Insurance Portability and Accountability Act (HIPAA) in the US and the General Data Protection Regulation (GDPR) in Europe.

In order to prevent unauthorised access and data breaches, AI systems must adhere to these standards by putting strong data encryption, safe data storage, and strict access controls in place. Blockchain and artificial intelligence (AI) together have been proposed as a potential remedy to ensure data security and increase transparency in healthcare transactions. Blockchain technology can provide an immutable record of all data interactions, thereby ensuring data integrity and traceability. However, the integration of blockchain and AI also presents certain challenges, including scalability issues and the necessity for substantial computational resources.

A crucial element of data security is the anonymisation and de-identification of patient data, which must be achieved in order to safeguard individual identities while facilitating meaningful data analysis. It is imperative that AI algorithms are designed in such a way that they can handle anonymised data without compromising the accuracy of their predictions and recommendations. In order to keep patients' trust and adhere to regulatory requirements, it is critical to strike a balance between the value of data and patient privacy protection[43].

7.2 Ethical Use of AI

The ethical application of AI in healthcare requires that concerns about responsibility, justice, and prejudice be taken into account. The training data used to develop AI algorithms may contain biases that could lead to discriminatory outcomes. For instance, an AI system trained on a patient data set primarily composed of men might not be able to predict treatment outcomes for female patients with the same accuracy. It is of the utmost importance to guarantee that AI models are developed using diverse and representative datasets in order to mitigate these biases[44].

The assurance of fairness in AI models necessitates the implementation of a continuous monitoring and validation process, with the objective of detecting and correcting any identified biases. To improve the equity of AI systems, strategies like adversarial debiasing and fairness-aware machine learning can be used. To further promote confidence between patients and healthcare professionals, it is crucial to guarantee transparency in AI decision-making processes. Explainable AI (XAI) techniques facilitate the elucidation of the rationale behind AI system decisions, thereby fostering clinician comprehension and trust in the AI's recommendations[45].

Furthermore, ethical issues may emerge in instances where AI systems render decisions that have ramifications for patient care. The question of accountability is of paramount importance. Who is held responsible if an AI-driven decision results in an adverse patient outcome? It is imperative to establish transparent and comprehensive guidelines and regulatory frameworks for the ethical utilisation of AI in healthcare in order to effectively address these challenges. It is incumbent upon healthcare institutions to establish ethical committees and governance structures to oversee the deployment and use of AI technologies.

7.3 Legal Implications

The legal implications of implementing AI in healthcare are complex and multifaceted, encompassing a range of issues related to liability, consent, and regulatory compliance. A principal legal issue pertains to the question of liability when artificial intelligence (AI) systems are engaged in clinical decision-making processes. Determining who is legally liable for an incorrect diagnosis or treatment recommendation made by an AI system—the AI developer, the healthcare professional, or the institution—can be difficult. It is imperative that clear legal frameworks be established to delineate responsibility and ensure accountability in such scenarios[46].

Another crucial legal concern is that of informed consent. It is crucial that patients receive thorough information on the use of AI in their treatment, along with a clear explanation of the possible dangers and advantages. In order to gain informed permission, it is necessary to ensure that patients are aware of how their data will be used and to explain how AI works in the diagnosis and treatment process. Such transparency is vital for the maintenance of patient trust and compliance with ethical standards[47].

All applications of artificial intelligence (AI) in the healthcare industry must abide by data protection laws, such as the Health Insurance Portability and Accountability Act (HIPAA) and the General Data Protection Regulation (GDPR). In order to maintain confidentiality and privacy, these requirements require that patient data be handled with the highest care and attention. Designing AI systems with features like data encryption, access restrictions, and audit trails in compliance with the aforementioned regulatory standards is essential. It is essential to conduct regular audits and assessments to guarantee ongoing compliance and to address any emerging legal and ethical concerns[48].

Because AI is a global technology, there are a lot of additional legal problems that arise from the fact that different countries have varied standards and legislation for data protection and AI implementation. International collaborations in AI-driven healthcare must navigate the complex regulatory landscapes that exist in different countries, ensuring compliance with local laws while maintaining the integrity and effectiveness of AI systems. The harmonisation of international standards and regulations can facilitate the broader adoption of AI in healthcare, thereby promoting innovation while safeguarding patient rights[49].

8. Future Directions and Research

8.1 Integration of Wearable Technologies

Wearable technologies are at the vanguard of efforts to enhance personalised care in healthcare. A variety of physiological characteristics, such as heart rate, blood pressure, and activity levels, can be tracked in real time by these gadgets, which include smartwatches, fitness trackers, and biosensors. Wearable device data can be utilized to deliver individualized health insights and treatments, which can enhance patient outcomes and facilitate ongoing monitoring beyond clinical environments.

The potential of wearable devices to enhance personalised care is considerable. For example, AI-driven wearables have the capacity to detect the initial indications of a decline in health and to alert the relevant healthcare professionals or patients to take the necessary preventive measures. According to a study, the combination of wearable AI and technology could significantly improve senior care by offering individualized health recommendations and ongoing monitoring, which could lower the likelihood of unfavorable health events. Through the provision of real-time feedback and tailored interventions, the use of wearable devices in the management of chronic illnesses, such as diabetes and cardiovascular disease, has shown effective in improving disease management and patient compliance[50].

It is particularly noteworthy that innovative wearable technologies are being developed for elderly patients. For instance, fall detection systems integrated into wearable devices can alert caregivers or emergency services when a fall occurs, facilitating the provision of timely assistance to prevent further injury[51]. Furthermore, wearable devices that monitor sleep patterns and physical activity can assist in the identification and management of conditions such as sleep apnoea and sedentary behaviour, which are prevalent in elderly populations[52]. The incorporation of AI into these technologies facilitates more precise and expedient data analysis, thereby enhancing the overall efficacy of wearable devices in the domain of personalised healthcare.

8.2 Enhancing Personalized Care

It is anticipated that future developments in AI -driven personalised treatment plans will have a transformative impact on healthcare, offering highly individualised care based on comprehensive data analysis. The idea of personalized medicine—which entails customizing medical care to each patient's unique characteristics—is becoming more and more realistic with the introduction of artificial intelligence. Artificial intelligence algorithms are capable of analysing genetic information, lifestyle factors and clinical data in order to develop bespoke treatment plans that optimise therapeutic outcomes[53].

One area in which AI has demonstrated considerable potential is in the field of oncology. With the help of artificial intelligence-driven models, more accurate and successful cancer treatments can be implemented by predicting how patients would react to various cancer treatments based on their genetic profiles and clinical histories. Similar to this, AI has the ability to analyze patient data in the field of cardiology to determine who is most vulnerable to cardiovascular events. This could then lead to the recommendation of personalised preventive measures, such as lifestyle modifications or medication adjustments[54]. By minimising the need for trial and error and maximising treatment efficacy, these advancements in customized care are expected to improve patient outcomes and save healthcare costs.

It is imperative that there be cross-disciplinary collaboration in order to ensure the successful implementation of AI-driven personalised care. The integration of insights from fields such as genomics, bioinformatics, and behavioural science can facilitate a comprehensive understanding of patient health, thereby informing the development of more effective interventions. For example, collaborative efforts between geneticists and AI specialists have resulted in the creation of predictive models capable of identifying individuals at risk for genetic disorders, thereby facilitating early intervention and prevention. The development of individualized treatment and the guarantee that AI technologies are fully utilized depend heavily on such multidisciplinary approaches.

8.3 Economic and Policy Considerations

The incorporation of AI in healthcare has significant and intricate economic ramifications. AI can, on the one hand, lower healthcare costs by increasing productivity, boosting diagnostic precision, and averting expensive complications. To illustrate, AI-driven predictive analytics has the capacity to identify patients at high risk and facilitate early interventions, which can result in a reduction in hospital readmissions and the costs associated with them. AI also has the ability to lower operating costs for healthcare providers by streamlining administrative tasks like scheduling and billing.

Nevertheless, the deployment of AI in healthcare also gives rise to economic challenges. The initial investment in AI technologies can be considerable, with ongoing costs associated with maintenance, updates and training healthcare professionals in the effective utilisation of these systems. It is also imperative to guarantee equitable access to AI-driven healthcare solutions. It is incumbent upon policymakers to address disparities in access to AI technologies in order to prevent the widening of the healthcare gap between different socioeconomic groups.

It is advised that governmental measures aimed at easing the integration of AI in healthcare should place an emphasis on innovation promotion while also ensuring patient data security and confidentiality. Establishing clear and thorough rules for the development and application of AI in healthcare is crucial for governments and regulatory agencies. These guidelines must encompass clear standards for data security, algorithm transparency, and ethical considerations. Incentives for research and development, as well as funding for pilot projects, can facilitate the accelerated adoption of AI technologies and demonstrate their value in improving healthcare outcomes.

8.4 Empirical Testing and Validation

It is of paramount importance to conduct empirical research in order to validate the effectiveness of AI tools in the field of healthcare. It is essential that rigorous testing and validation are conducted to guarantee that AI algorithms function consistently and accurately in a range of clinical settings and populations. Randomized controlled trials (RCTs) and real-world implementation studies can provide robust evidence of the efficacy and safety of AI-driven interventions.

It is of particular importance to conduct broader implementation studies in order to assess the generalisability of AI tools. In order to assess AI systems' performance under real-world circumstances, these research involve deploying them in a variety of healthcare settings, such as community health centers, hospitals, and primary care clinics. Such research can identify potential impediments to implementation, including interoperability issues with existing health IT systems or resistance from healthcare providers.

Furthermore, the long-term effects of AI on healthcare delivery and patient outcomes should be the focus of validation research. To find out if AI interventions result in long-term gains in health and quality of life, longitudinal studies can be used to monitor patient health over time. Furthermore, these studies can evaluate the cost-effectiveness of AI tools by comparing healthcare utilisation and expenditure before and after AI implementation.

In summary, wearable technology integration, individualized treatment advancements, legislative and economic issues, and the significance of empirical testing and validation are all part of the future trajectory of artificial intelligence in healthcare. AI has the power to drastically improve patient outcomes, drastically improve healthcare delivery, and completely change the healthcare industry by tackling these issues.

9. Conclusion

9.1 Summary of Findings

The incorporation of artificial intelligence (AI) into healthcare has significantly transformed patient care, particularly in managing chronic illnesses and sarcopenia. AI's ability to analyze vast data with precision enhances diagnostic accuracy, personalizes treatment plans, and predicts disease progression. For chronic diseases like cardiovascular conditions, diabetes, and COPD, AI-driven tools enable early detection, continuous monitoring, and individualized treatment, improving patient outcomes and reducing healthcare costs by preventing complications. In managing sarcopenia, AI utilizes sophisticated imaging and machine learning for early diagnosis and personalized therapies. AI-powered wearable technologies and remote monitoring systems provide continuous data on patients' physical activity and health, facilitating timely interventions and improving elderly patients' quality of life. These tools empower patients to actively manage their health, fostering a collaborative care approach. AI's integration of diverse data sources and predictive capabilities enhances risk assessment and mitigation, improving patient safety, care quality, and overall healthcare efficiency.

9.2 Future Outlook

AI in healthcare has a bright future ahead of it, thanks to developments in AI technology and easier access to health data that will improve the treatment of sarcopenia and chronic illness. Integrating AI with blockchain and IoT will improve data security, transparency, and interoperability, creating more robust AI applications. To fully realize AI's potential, investment in interdisciplinary research and collaboration is essential, bringing together experts in medicine, data science, bioinformatics, and ethics to develop ethically sound, patient-centered AI tools. Future research should focus on expanding the evidence base for AI through large-scale implementation studies and randomized controlled trials, assessing AI interventions' efficacy, safety, and long-term impact on health outcomes and cost-effectiveness. This robust evidence will inform optimal practices and policy recommendations for sustainable AI integration in healthcare. AI's ability to enhance diagnostics, personalize treatment, and predict disease progression offers significant benefits, but achieving its full potential requires continued research, collaboration, and solutions prioritizing patient safety, data privacy, and ethical considerations, ultimately transforming healthcare with improved patient outcomes and system efficiency.

References

[1] Jeong-Kyun Kim, Myung-Nam Bae, K. Lee, Jae-Chul Kim, S. Hong. Explainable Artificial Intelligence and Wearable Sensor-Based Gait Analysis to Identify Patients with Osteopenia and Sarcopenia in Daily Life. Biosensors. 2022. DOI: 10.3390/bios12030167

[2] Yangbing Hu. Robotics and Artificial Intelligence Applications in Remote Data Acquisition, Data Analysis and Disease Early Warning. IEEE. 2022. DOI: 10.1109/EEBDA53927.2022.9745020

[3] K. Kioskli, Spyridon Papastergiou. A Swarm Artificial Intelligence Approach for Effective Treatment of Chronic Conditions. IEEE. 2023. DOI: 10.1109/DRCN57075.2023.10108128

[4] Olga A. Sawicki, Angelina Mueller, R. Klaassen-Mielke, Anastasiya Glushan, F. Gerlach, M. Beyer, M. Wensing, Kateryna Karimova. Strong and sustainable primary healthcare is associated with a lower risk of hospitalization in high risk patients. Scientific Reports. 2021. DOI: 10.1038/s41598-021-83962-y

[5] Susan Tran-Nguyen, Stephen Edward Asha. A collaborative pharmacist-led intervention to prevent hospital readmissions among elderly patients discharged from the emergency department: a retrospective cohort study. Scientific Reports. 2024. DOI: 10.1038/s41598-024-64968-8

[6] A. Romanenko, Ю. Л. Кучин, К. Ю. БЄлка, И. А. Токар. Perioperative pain management in elderly patients with a proximal femoral fracture: evidence review. Pain Medicine Journal. 2020. DOI: 10.31636/pmjua.v4i4.2

[7] T. Borg, J. Eisold, Yusuf Miyanjo, E. Pappa. The effect of COVID-19 on surgical management of skin cancers of

the head, face and neck in elderly patients. Skin Health and Disease. 2023. DOI: 10.1002/ski2.175

[8] Zhiyang Cong, Mingshu Huo, Xing Jiang, Hongyu Yu. Factors associated with the level of self-management in elderly patients with chronic diseases: a pathway analysis. BMC Geriatrics. 2024. DOI: 10.1186/s12877-024-04956-9 .

[9] Li Chen, Yinghua Gong, Liangzhuo Yuan. Health behaviour and its determinants in elderly patients with chronic diseases: evidence from Jiangsu Province, China. BMC Geriatrics. 2022. DOI: 10.1186/s12877-022-03010-w

[10] Xiaoming Wang, Cun-yuan Zhang. Chinese expert consensus on the diagnosis and treatment of chronic heart failure in elderly patients (2021). Aging Medicine. 2022. DOI: 10.1002/agm2.12215

[11] Yongli Wang, Xiaodan Li, Dongmei Jia, Bei-lei Lin, B. Fu, Bei Qi, Zhenxiang Zhang. Exploring polypharmacy burden among elderly patients with chronic diseases in Chinese community: a cross-sectional study. BMC Geriatrics. 2021. DOI: 10.1186/s12877-021-02247-1

[12] J. Plaza-Zamora, I. Legaz, E. Osuna, M. Pérez-Cárceles. Medication literacy in elderly patients with chronic diseases: a community pharmacy perspective. Research Square. 2020. DOI: 10.21203/rs.2.20968/v1

[13] Xin Wang, Shihui Wang, Xiaojia Yu, Zhuo Ma, Huaguang Wang, Jing Yang, Lihong Liu. Impact of pharmacist-led medication therapy management in ambulatory elderly patients with chronic diseases. British Journal of Clinical Pharmacology. 2020. DOI: 10.1111/bcp.14709.

[14] Shaoliang Tang, Yun Xu, Zhengjun Li, Tongling Yang, David Qian. Does Economic Support Have an Impact on the Health Status of Elderly Patients with Chronic Diseases in China? - Based on CHARLS (2018) Data Research. Frontiers in Public Health. 2021. DOI: 10.3389/fpubh.2021.658830

[15] Zhixu Hu, Hang Qiu, Liya Wang, Minghui Shen. Network analytics and machine learning for predicting length of stay in elderly patients with chronic diseases at point of admission. BMC Medical Informatics and Decision Making. 2022. DOI: 10.1186/s12911-022-01802-z

[16] Lanyu Lu, Bowei Liu, F. Yin. Alternative skeletal muscle index for sarcopenia diagnosis in elderly patients with type 2 diabetes mellitus: A pilot study. Frontiers in Endocrinology. 2023. DOI: 10.3389/fendo.2023.1083722

[17] Hiroyuki Inoshita, Daisuke Asaoka, Kei Matsuno, N. Yanagisawa, Yusuke Suzuki, Katsumi Miyauchi. Cross-Sectional Study on the Association between Dietary Patterns and Sarcopenia in Elderly Patients with Chronic Kidney Disease Receiving Conservative Treatment. Nutrients. 2023. DOI: 10.3390/nu15234994

[18] Xintian Cai, Junli Hu, Mengru Wang, Wen Wen, Jingyu Wang, Wenbo Yang, Yujie Dang, Q. Luo, Jing Hong, Nan-fang Li. Association between the sarcopenia index and the risk of stroke in elderly patients with hypertension: a cohort study. Aging. 2023. DOI: 10.18632/aging.204587

[19] Yang Hou, Jia Xiang, Bo Wang, Shoufeng Duan, Rouxuan Song, Wenhu Zhou, Songwen Tan, Binsheng He. Pathogenesis and comprehensive treatment strategies of sarcopenia in elderly patients with type 2 diabetes mellitus. Frontiers in Endocrinology. 2024. DOI: 10.3389/fendo.2023.1263650

[20] G. Ma, Lingling Zou, W. Dai, Z-Z Wang, Y-H Cao. The association between glucose fluctuation with sarcopenia in elderly patients with type 2 diabetes mellitus. European Review for Medical and Pharmacological Sciences. 2023. DOI: 10.26355/eurrev_202303_31557

[21] Satoshi Ida, K. Imataka, Shoki Morii, Keitaro Katsuki, Kazuya Murata. Frequency and Overlap of Cachexia, Malnutrition, and Sarcopenia in Elderly Patients with Diabetes Mellitus: A Study Using AWGC, GLIM, and AWGS2019. Nutrients. 2024. DOI: 10.3390/nu16020236

[22] A. Kamiya, Tsutomu Hayashi, Ryota Sakon, K. Ishizu, T. Wada, Sho Otsuki, Y. Yamagata, H. Katai, T. Yoshikawa. Acceleration of sarcopenia in elderly patients who develop asymptomatic

pneumonia shadow within one year after surgery for early gastric cancer. BMC Surgery. 2023. DOI: 10.1186/s12893-023-02096-2

[23] Yogesh Kumar, Apeksha Koul, Ruchika Singla, M. Ijaz. Artificial intelligence in disease diagnosis: a systematic literature review, synthesizing framework and future research agenda. Journal of Ambient Intelligence and Humanized Computing. 2022. DOI: 10.1007/s12652-021-03612-z

[24] M. Rakhimov, Ravshanjon Akhmadjonov, Shahzod Javliev. Artificial Intelligence in Medicine for Chronic Disease Classification Using Machine Learning. IEEE. 2022. DOI: 10.1109/AICT55583.2022.10013587

[25] Yiqing Xu, Zalizah Awang Long, D. Setyohadi. A Comprehensive Review on the Application of Artificial Intelligence in Chronic Obstructive Pulmonary Disease (COPD) Management. IEEE. 2024. DOI: 10.1109/IMCOM60618.2024.10418416

[26] Yi Xie, Lin Lu, F. Gao, Shuang-jiang He, Hui-juan Zhao, Ying Fang, Jiaming Yang, Y. An, Z. Ye, Zhe Dong. Integration of Artificial Intelligence, Blockchain, and Wearable Technology for Chronic Disease Management: A New Paradigm in Smart Healthcare. Journal of Zhejiang University Science B. 2021. DOI: 10.1007/s11596-021-2485-0

[27] Natalie Nathan, Michael Saring, Noam Savion-Gaiger, Kira Radinsky, Alma Peri. Artificial Intelligence in Healthcare: A New Frontier in Predicting and Managing Chronic Diseases. PubMed. 2024. DOI: 10.1097/JPA.0000000000000208

[28] Dileep Kumar Murala, S. K. Panda, Sujata Priyambada Dash. MedMetaverse: Medical Care of Chronic Disease Patients and Managing Data Using Artificial Intelligence, Blockchain, and Wearable Devices State-of-the-Art Methodology. IEEE Access. 2023. DOI: 10.1109/ACCESS.2023.3340791

[29] Jingyi Wen, Dong Liu, Qianni Wu, Lanqin Zhao, Wai Cheng Iao, Haotian Lin. Retinal image-based artificial intelligence in detecting and predicting kidney diseases: Current advances and future perspectives. Visual Informatics. 2023. DOI: 10.1002/VIW.20220070

[30] Amanda Kote. Innovation in Healthcare through Technology and Artificial Intelligence – Case Study: VitalView Blood Pressure Monitoring System. Ingenious Healthcare. 2024. DOI: 10.58944/eqld4771

[31] Diego Lopez-Bernal, David C. Balderas, P. Ponce, Mario Rojas, A. Molina. Implications of Artificial Intelligence Algorithms in the Diagnosis and Treatment of Motor Neuron Diseases—A Review. Life. 2023. DOI: 10.3390/life13041031

[32] M. Cingolani, R. Scendoni, P. Fedeli, Fabio Cembrani. Artificial intelligence and digital medicine for integrated home care services in Italy: Opportunities and limits. Frontiers in Public Health. 2023. DOI: 10.3389/fpubh.2022.1095001

[33] Basma Boukenze. Earlier Forecasting of Chronic Kidney Failure: Performance of artificial intelligence in healthcare. IEEE CiSt. 2023. DOI: 10.1109/CiSt56084.2023.10409921

[34] Leelkanth Dewangan, Mahesh V. Shitole, J. P. Patra, Jalaluddin Khan, Gopesh Kumar Dawda, Prasanta Kumar Parida. Machine Learning-Based Risk Prediction for Coronary Heart Disease Using Clinical Data. IEEE. 2023. DOI: 10.1109/ICAIIHI57871.2023.10488969

[35] Ranieri Guerra. Enhancing risk management in hospitals: leveraging artificial intelligence for improved outcomes. Italian Journal of Medicine. 2024. DOI: 10.4081/itjm.2024.1721

[36] Julia M. Puaschunder. The Future of Artificial Intelligence in International Healthcare: An Index. SSRN. 2020. DOI: 10.2139/ssrn.3623530

[37] Rejath Jose, Faiz Syed, Anvin Thomas, Milan Toma. Cardiovascular Health Management in Diabetic Patients with Machine-Learning-Driven Predictions and Interventions. Applied Sciences. 2024. DOI: 10.3390/app14052132

[38] Israa Abu-elezz, Asmaa Hassan, B. Jaber, Mohamad Sharique, Alaa A. Abd-alrazaq, Mowafa J Househ, T. Alam, Zubair Shah. Contribution of Artificial Intelligence in Pregnancy: A Scoping Review. IOS Press. 2022. DOI: 10.3233/shti210927

[39] X. Huo, H. Krumholz, X. Bai, E. Spatz, Q. Ding, P. Horak, Weigang Zhao, Q. Gong, Haibo Zhang, Xiaofang Yan, Ying

Sun, Jiamin Liu, Xuekun Wu, Wenchi Guan, Xiuling Wang, Jing Li, Xi Li, J. Spertus, F. Masoudi, Xin Zheng. Effects of Mobile Text Messaging on Glycemic Control in Patients with Coronary Heart Disease and Diabetes Mellitus. Circulation: Cardiovascular Quality and Outcomes. 2019. DOI: 10.1161/CIRCOUTCOMES.119.005805

[40] S. Elghamrawy, A. Darwish, A. Hassanien. Monitoring COVID-19 Disease Using Big Data and Artificial Intelligence-Driven Tools. Springer. 2020. DOI: 10.1007/978-3-030-63307-3_10

[41] A. S. Yadav, Anupam Swami, Navin Ahlawat, Priyanka Agarwal. A Comprehensive Review of Advancements in Bladder Cancer Screening: Harnessing Mathematics and Artificial Intelligence for Early Detection and Personalized Management. GeNex. 2024. DOI: 10.55248/gengpi.5.0624.1547

[42] Wan D. Bae, Shayma Alkobaisi, Matthew Horak, Choon-Sik Park, Sungroul Kim, Joel Davidson. Predicting Health Risks of Adult Asthmatics Susceptible to Indoor Air Quality Using Improved Logistic and Quantile Regression Models. Life. 2022. DOI: 10.3390/life12101631

[43] K. Drabiak, Skylar Kyzer, Valerie Nemov, I. E. El Naqa. AI and ML ethics, Law, Diversity, and Global Impact. British Journal of Radiology. 2023. DOI: 10.1259/bjr.20220934

[44] Aloysius Ochasi, A. J. Mahamadou, Russ B. Altman. Justice in Healthcare Artificial Intelligence in Africa. arXiv. 2024. DOI: 10.48550/arXiv.2406.10653

[45] Onyekachukwu R. Okonji, Kamol Yunusov, Bonnie Gordon. Applications of Generative AI in Healthcare: algorithmic, ethical, legal and societal considerations. TechRxiv. 2024. DOI: 10.36227/techrxiv.171527587.75649430/v1

[46] Mansi Dhingra. Bioethical Considerations of Artificial Intelligence in Healthcare Management. International Journal of Science and Research. 2023. DOI: 10.21275/sr23709144913

[47] Hisham E Hasan, Deema Jaber, O. Khabour, K. Alzoubi. Ethical considerations and concerns in the implementation of AI in pharmacy practice: a cross-sectional study. BMC Medical Ethics. 2024. DOI: 10.1186/s12910-024-01062-8

[48] Krati Dubey, Chaitali B. Kasar, Guravaiah Thulluri, Anuradha Yesugad, Mehaboob Karishma, Dipanjali Padhi. Leveraging Big Data for Effective Healthcare Management with Artificial Intelligence. IEEE. 2023. DOI: 10.1109/ICAIIHI57871.2023.10489731

[49] Iqra Basharat, Subhan Shahid. AI-enabled chatbots healthcare systems: an ethical perspective on trust and reliability. Journal of Health Organization and Management. 2024. DOI: 10.1108/jhom-10-2023-0302

[50] M. Rincón, R. Martínez-Tomás, J. M. Ferrández. Assistive intelligence for the elderly. Expert Systems. 2020. DOI: 10.1111/exsy.12535

[51] Thierry Moulin, J. Dobson, J. Hixson, Theodoros N. Arvanitis. Digital Health: The journal's pioneering journey 6 years on. Digital Health. 2021. DOI: 10.1177/20552076211034034

[52] Ritika R. Chaturvedi, Wendy PhD. Consumer digital health and person generated health data – opportunities and challenges for sleep disparities research and clinical practice. Sleep. 2022. DOI: 10.1093/sleep/zsac079.056

[53] Wasim Alamgir, A. Mohyuddin. Healthcare Analytics: Applications and Challenges. Life and Science. 2022. DOI: 10.37185/lns.1.1.263

[54] Zhijun Yan, Roberta Bernardi, Ni Huang, Younghoon Chang. Guest editorial: The bright side and the dark side of digital health. Internet Research. 2021. DOI: 10.1108/intr-12-2021-682.